HAG
BTAI icon

HighPoint Advisor Group’s BioXcel Therapeutics BTAI Stock Holding History

HighPoint Advisor Group’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-762
Closed -$354K – 570
2021
Q2 		$354K Sell
762
-30
-4% -$16.4K 0.04% 367
2021
Q1 		$455K Buy
792
+21
+3% +$16.9K 0.05% 292
2020
Q4 		$737K Sell
771
-64
-8% -$49.9K 0.09% 183
2020
Q3 		$717K Sell
835
-303
-27% -$227K 0.13% 134
2020
Q2 		$974K Buy
1,138
+658
+137% +$429K 0.21% 92
2020
Q1 		$236K Buy
+480
New +$173K 0.06% 263

Other funds holding BTAI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $9.43B AUM 69.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

HighPoint Advisor Group's BTAI Position: Q3 2021 in Review

HighPoint Advisor Group sold out of BioXcel Therapeutics (BTAI) in Q3 2021, closing a stake of 762 shares — an estimated $354K sold.

HighPoint Advisor Group first reported a position in BTAI in Q1 2020 and held it in 6 quarters. The position peaked at $974K in Q2 2020. 103 funds tracked by Wall St. Rank hold BTAI as of Q3 2021.

  • HighPoint Advisor Group reported no remaining BioXcel Therapeutics position as of Q3 2021 after selling out during the quarter.
  • HighPoint Advisor Group sold 762 BioXcel Therapeutics shares in Q3 2021, an estimated $354K.
  • HighPoint Advisor Group first reported a position in BioXcel Therapeutics in Q1 2020 and held it in 6 quarters.
  • HighPoint Advisor Group's BioXcel Therapeutics position peaked at $974K in Q2 2020.
  • 103 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q3 2021.

Based on HighPoint Advisor Group's 13F filing for Q3 2021, filed 15 Nov 2021.